Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label phase 2 rituximab trial in severe resistant pemphigus vulgaris or foliaceus
2007-005711-26Phase 2Active
- Sponsor
- Fondazione Luigi Maria Monti IDI-IRCCS
- Start
- Feb 2008
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of rituximab in pemphigus vulgaris (PV) and pemphigus foliaceus (PF), sponsored by Fondazione Luigi Maria Monti IDI-IRCCS. Primary endpoint: Complete remission. Started Feb 2008; status: active.
02
Drugs
rituximab
03
Conditions
pemphigus vulgaris (PV)pemphigus foliaceus (PF)
Beyond the preview
Go deeper on 2007-005711-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-005711-26.